TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00851266

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V512
Description: Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to V512
Description: Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
Study: NCT02382471

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: 4 cap 1 g Omega-3 per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 cap 1 g Placebo(paraffin) per day for 2 months
Study: NCT03198637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium's monitoring by TOF (train-of-four) WATCH device.
Description: Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clinical assessment
Study: NCT00635388

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: oral, placebo, once/day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus (Probiotic 1)
Description: oral, Lactobacillus, once/day for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus and Bifidobacterium (Probiotic 2)
Description: oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
Study: NCT02872181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine
Description: Placed in Supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine
Description: Placed in Supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine
Description: Placed in Supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left uterine displacement
Description: Placed in 15 degrees left uterine displacement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left uterine displacement
Description: Placed in 15 degrees left uterine displacement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left uterine displacement
Description: Placed in 15 degrees left uterine displacement
Study: NCT02012205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wet cupping
Description: Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
Study: NCT02005354

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Trans-cutaneous Electrical Nerve Stimulation (TENS)
Description: Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-cutaneous Electrical Nerve Stimulation (TENS)
Description: Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (\>50Hz and below the pain threshold for the patient).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Description: All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Description: All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
Study: NCT03695133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based interventions
Description: 1. Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~2. Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented.
Study: NCT02832297

Intervention type: OTHER
Group type: OTHER
Intervention: Vectra DA

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Study: NCT02015923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic resection
Description: Colonic cancer resection, R0 No surgical intervention on metastasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic resection
Description: Colonic cancer resection, R0 No surgical intervention on metastasis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy- scheme
Description: Chemotherapy, specified in each center with or without biological drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy- scheme
Description: Chemotherapy, specified in each center with or without biological drugs
Study: NCT03250650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTNS
Description: Transcutaneous tibial electric stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES+TTNS
Description: Transvaginal electric stimulation
Study: NCT01888471

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal swab sample
Description: Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal swab sample
Description: Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
Study: NCT02848508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03506516

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixing alcohol
Description: Alcoholic beverages, different types

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single type alcohol
Description: Alcoholic beverages, different types
Study: NCT00153764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cooper Complete One-A-Day Vitamin Supplement
Study: NCT00470951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open rectal resection
Description: open rectal resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic rectal resection
Description: laparoscopic assisted rectal resection
Study: NCT03521635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole SR
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole IR
Description: Tablets
Study: NCT02496013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NEB
Description: 68Ga-NEB were injected into the patients before the PET/CT scans
Study: NCT04830449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1904-2
Description: Take it once daily for 8 weeks orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2001-2
Description: Take it once daily for 8 weeks orally.
Study: NCT00317772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Phase I Starting Dose: 2 mg/m\^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days.
Study: NCT00514215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Days 1 \& 32

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: CT guided biopsy on days 1 \& 32

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery
Description: Days 1 and 32
Study: NCT00315133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunosuppression and autologous stem cell transplantation
Description: Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
Study: NCT00492349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
Study: NCT01495065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 750 mg
Description: Treatment A: 750 mg IV GSK2251052 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 1500 mg
Description: Treatment B: 1500 mg IV GSK2251052 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 1500 mg BID
Description: Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 2250 mg
Description: Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 3000 mg
Description: Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052 0.9% saline
Description: Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
Study: NCT06395350

Intervention type: DEVICE
Group type: OTHER
Intervention: Spire Health Monitor
Description: Use of Health Monitor is Assessed
Study: NCT04440553

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uniform random message delivery
Description: The uniform random intervention group receives feedback and motivational messages chosen from the messaging banks with equal probabilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement learning message delivery
Description: The adaptive intervention group receives messages chosen from the messaging banks by a reinforcement learning algorithm.
Study: NCT03215095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Medi4736)
Description: durvalumab 1500 mg IV every 4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodine (RAI)
Description: 100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
Study: NCT03019536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: Administered IV during the Positron Emission Tomography (PET) scan performed during screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: Administered IV during the Positron Emission Tomography (PET) scan performed during screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F 18
Description: Administered IV during the Positron Emission Tomography (PET) scan performed during screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered IV during the PET scan performed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered IV during the PET scan performed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: Administered IV during the PET scan performed during the study.
Study: NCT03959865

Intervention type: DRUG
Intervention: Long-acting GLP-1RA
Description: Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg

Intervention type: DRUG
Intervention: Short-acting GLP-1RA
Description: Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.

Intervention type: DRUG
Intervention: Human-based GLP-1RA
Description: Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
Study: NCT02946463

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Study: NCT03959865

Intervention type: DRUG
Intervention: Exendin-based GLP-1RA
Description: Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.

Intervention type: DRUG
Intervention: Fixed ratio BI/GLP-1RA combination
Description: Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)

Intervention type: DRUG
Intervention: Flexible BI/GLP-1RA combination
Description: GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
Study: NCT04274608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Intragastric injection of Botulinum toxin type A
Study: NCT02946463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Study: NCT04274608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Management Program
Description: 12 week weight management program
Study: NCT03656445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
Study: NCT03302559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinol Complex 0.5
Description: Retinol Complex 0.5 topically in the evening.
Study: NCT04458779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
Study: NCT03551366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linear
Description: The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear
Description: The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
Study: NCT02946463

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
Study: NCT03225469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reinforced family member education
Description: Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
Study: NCT01342523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS - telephone cessation quitline counseling
Description: Up to 5 total tobacco cessation counseling calls
Study: NCT04371419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messaging
Description: o The video messages each participant in one of the treatment groups sees will be randomized on the following dimensions. The different versions are clearly demarcated in the US Doctors Scripts document.~* Racial or ethnic identity of the doctor delivering the messages: concordant vs. discordant identity to the subject.~* Whether the message includes an acknowledgment of elephant in the room issues for each target group: trust in the medical system or fear of deportation.~* Whether the social distancing component of the message is delivered by Dr. Birx of the CDC or recorded by the MGH physicians.~* Whether individuals are given information about how representative individuals perceive mask wearers of color. This information comes from results of our nationally representative pilot survey.~* Some individuals in a control group will see messages later.
Study: NCT04274608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management Program
Description: 12 week weight management program